BackIllumina Overview
Illumina Inc

Illumina Target Price

Analysts' average 12-month price target for Illumina is $210.

Get informed when a big investor buys or sells

+ Follow

Share Price

$238.82

Average Target Price

$208.0012.9% downside

12 analysts in the last 4 months

High: $260 | Low: $160

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09UBS$2608.9% upsideOpen
2026-09-03Argus Research$2351.6% downsideOpen
2026-08-03Canaccord Genuity$20514.2% downsideOpen
2026-07-31RBC Capital$2303.7% downsideOpen
2026-07-31Bernstein$21510% downsideOpen
2026-07-31Guggenheim$2265.4% downsideOpen
2026-07-31Barclays$16033% downsideOpen
2026-07-17Leerink PartnersPuneet Souda$21012.1% downsideOpen
2026-07-14Canaccord GenuityKyle Mikson$19020.4% downsideOpen
2026-06-29Guggenheim$20016.3% downsideOpen
2026-06-26Bernstein$18522.5% downsideOpen
2026-06-01Guggenheim$18024.6% downsideOpen
2026-05-14RBC Capital$17028.8% downsideOpen
2026-05-14DaiwaIllumina to Outperform$15535.1% downsideOpen
2026-05-01Canaccord Genuity$14041.4% downsideOpen
2026-05-01Barclays$12248.9% downsideOpen
2026-02-09Piper Sandler$17028.8% downsideOpen
2026-02-06Robert W. BairdCatherine Ramsey Schulte$13742.6% downsideOpen
2026-02-06UBS$13543.5% downsideOpen
2026-02-06Evercore ISI$15037.2% downsideOpen
2026-01-26GuggenheimSubbu Nambi$17028.8% downsideOpen
2026-01-26Canaccord Genuity$15037.2% downsideOpen
2026-01-20Stifel NicolausDaniel Arias$15535.1% downsideOpen
2026-01-05Evercore ISIVijay Kumar$15535.1% downsideOpen
2026-01-05Guggenheim$14439.7% downsideOpen
2025-12-15Barclays$11053.9% downsideOpen
2025-10-31Evercore ISIVijay Kumar$14240.5% downsideOpen
2025-10-31Robert W. Baird$10954.4% downsideOpen
2025-10-31UBS$12049.8% downsideOpen
2025-10-31Canaccord Genuity$11253.1% downsideOpen
2025-10-31BarclaysLuke Sergott$10058.1% downsideOpen
2025-10-24Robert W. Baird$10556% downsideOpen
2025-10-02Barclays$9560.2% downsideOpen
2025-09-02RBC Capital$12448.1% downsideOpen
2025-08-04Morgan Stanley$10556% downsideOpen
2025-08-04Stephens$11053.9% downsideOpen
2025-06-24BarclaysLuke Sergott$8564.4% downsideOpen
2025-05-15Piper SandlerDavid Westenberg$18522.5% downsideOpen
2025-03-11Canaccord Genuity$11551.8% downsideOpen
2025-03-05Robert W. Baird$9062.3% downsideOpen
2025-02-28National Bank$10058.1% downsideOpen
2025-02-28HSBC$10058.1% downsideOpen
2025-02-03BarclaysLuke Sergott$13045.6% downsideOpen
2025-01-10BernsteinEve Burstein$14041.4% downsideOpen
2025-01-02Evercore ISIVijay Kumar$18024.6% downsideOpen
2024-11-06Robert W. BairdCatherine Ramsey Schulte$13941.8% downsideOpen
2024-11-05Canaccord GenuityKyle Mikson$14539.3% downsideOpen
2024-11-05BarclaysLuke Sergott$14539.3% downsideOpen
2024-10-17HSBCShubhangi Gupta$18024.6% downsideOpen
2024-08-28Argus ResearchJasper Hellweg$15037.2% downsideOpen

Illumina (ILMN) FAQ

Illumina posts a target price of $210. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $210 for ILMN means covering analysts, on average, see the stock 12.9% downside of $238.82 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ILMN's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Illumina's other metric pages and overview cover the third.

Judging Illumina against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $210 here, then scan peer and history charts to see if the gap is persistent.